Internal Medicine, Pulmonary Disease · Indianapolis, IN
NPI
1942268172
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
1801 N. Senate Blvd, Suite 2000
Indianapolis, IN, 46202
Phone (317) 962-9700
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
196 services
Medicare patients, 2024
75
Average age 64
Drug cost, 2024
$13.1M
1,824 prescriptions
Company payments, 2025
$64.99
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Roberto F Machado was code 99215 (office e&m - established), 55 times for 28 patients. In total Roberto F Machado billed 196 services in 16 codes, and Medicare paid $20K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 55 | 28 | $129.75 | $7,136 |
| 99233 Hospital E&M - Subsequent | Facility | 47 | 22 | $87.10 | $4,094 |
| 99291 Critical Care E&M | Facility | 37 | 16 | $144.72 | $5,355 |
| 94618 Pulmonary Function Testing | Office | 16 | 13 | $25.08 | $401 |
| 99214 Office E&M - Established | Office | 14 | 14 | $69.94 | $979 |
By year: 2022 $34K for 327 services; 2023 $30K for 314 services; 2024 $20K for 196 services.
Medicare prescription drug claims, 2024
In 2024, the drug Roberto F Machado prescribed most often to Medicare patients was Opsumit (Macitentan), with 324 prescriptions and refills. In total Roberto F Machado wrote 1,824 Medicare prescriptions that cost $13.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Opsumit Macitentan | 324 | 324 | 33 | $4.0M |
| Orenitram Er Treprostinil Diolamine | 172 | 172 | 13 | $2.0M |
| Tadalafil Generic | 163 | 183 | 17 | $88K |
| Sildenafil Citrate Generic | 150 | 241 | 29 | $50K |
| Adempas Riociguat | 118 | 118 | 12 | $1.6M |
| Winrevair Sotatercept-Csrk | 105 | 105 | 15 | $1.8M |
| Ambrisentan Generic | 103 | 109 | 12 | $149K |
| Spironolactone Generic | 91 | 220 | 26 | $883 |
| Uptravi Selexipag | 65 | 65 | Under 11 | $1.5M |
| Furosemide Generic | 54 | 145 | 16 | $296 |
| Potassium Chloride Generic | 37 | 83 | 12 | $4,501 |
| Torsemide Generic | 32 | 94 | 12 | $1,787 |
| Tyvaso Dpi Treprostinil | 30 | 30 | Under 11 | $669K |
| Letairis Ambrisentan | 25 | 25 | Under 11 | $325K |
| Jardiance Empagliflozin | 22 | 28 | Under 11 | $17K |
Brand drugs: 986 claims; generic drugs: 838 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Roberto F Machado $64.99 ($64.99 in general payments such as food, travel and fees) from 1 company. The largest payer was Actelion Pharmaceuticals US, Inc. with $64.99.
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. JNJ | 1 | $64.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.